Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

By Wei-Jia Kong, Jing Wei, P. Abidi, Meihong Lin, S. Inaba, Cong Li, Yanling Wang, Zizheng Wang, S. Si, Huaining Pan and 6 more. Nature Medicine, 2004

1,383 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/27e5717084a200f1c6608f9a1e67116037af1d88

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Jakóbisiak
2. Witold Lasek

In Surgery

1. Jianping Ye
2. Bruce E. Kemp
3. G. Steinberg

Citations in the corpus

• AMPK in Health and Disease. (2009, background): “Since the constitutively active AMPK fragment 1 (1-312) is not activated by the PT1 compound, it is proposed that PT1 acts by reversing the autoinhibition of the AIS (313-335).”
• Efficacy of berberine in patients with type 2 diabetes mellitus. (2008, result): “This activity is similar to that reported elsewhere in vivo [17,18].”
• Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20 (2008, background): “ine—an agent that inhibits cholesterol synthesis but in an HMG-CoAR–independent mechanism [32]—significantly decreased rituximab-mediated CDC (Figure 3C).”
• Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States (2006, neutral): “(42) described the cholesterol-lowering properties of berberine.”
• Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine (2008, background): “The anticomplementary activity has been proposed as one of the possible mechanisms of this effect (Kostalova et al., 2001).”